Aptevo Therapeutics Inc <APVO.OQ> expected to post a loss of $83.20 a share - Earnings Preview
Aptevo Therapeutics Inc APVO.OQ APVO.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Aptevo Therapeutics Inc is for a loss of $83.20 per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Aptevo Therapeutics Inc is $420.00, about 99.5% above its last closing price of $2.14
This summary was machine generated August 8 at 15:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Investing in Artificial General Intelligence (AGI)
AGI promises transformative productivity and economic gains but carries unprecedented technical, ethical, and social risks.Significant exposure comes through tech giants, semiconductor leaders, and cloud infrastructure providers, fueling AGI research.
Investing in Edge Computing
Edge computing complements the cloud by reducing latency, saving bandwidth, and enhancing privacy for real-time applications. Growth is fueled by IoT expansion, 5G rollout, AI integration, and enterprise digital transformation.
What Is Worldcoin? Why Did WLD Surge Suddenly, and What’s Next?
Worldcoin is evolving from a “hype token” into a foundational layer for global identity. Its fusion of biometrics, blockchain, and financial inclusion has earned growing recognition from users and institutions. If it can overcome technical hurdles, launch real-world payment use cases, and stabilize
U.S. Stock Sector Strategy: The Outlook for Tech Stocks from a Macro Perspective
TradingKey - Against the backdrop of easing trade war tensions, sustained economic resilience, and the Federal Reserve's anticipated interest rate cuts, the U.S. stock market is expected to maintain its upward trajectory. At the sector level, we are optimistic about U.S. technology stocks...
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.
